AU2023235321A1 - Pharmaceutical recombinant human acid sphingomyelinase compositions and methods - Google Patents

Pharmaceutical recombinant human acid sphingomyelinase compositions and methods Download PDF

Info

Publication number
AU2023235321A1
AU2023235321A1 AU2023235321A AU2023235321A AU2023235321A1 AU 2023235321 A1 AU2023235321 A1 AU 2023235321A1 AU 2023235321 A AU2023235321 A AU 2023235321A AU 2023235321 A AU2023235321 A AU 2023235321A AU 2023235321 A1 AU2023235321 A1 AU 2023235321A1
Authority
AU
Australia
Prior art keywords
imac
rasm
cex
preparation
optimal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023235321A
Other languages
English (en)
Inventor
Kevin BROWER
Xiaoying Jin
Thomas M. WASYLENKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AU2023235321A1 publication Critical patent/AU2023235321A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B01D15/203—Equilibration or regeneration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2023235321A 2022-03-18 2023-03-17 Pharmaceutical recombinant human acid sphingomyelinase compositions and methods Pending AU2023235321A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263321636P 2022-03-18 2022-03-18
US63/321,636 2022-03-18
PCT/US2023/064657 WO2023178325A1 (en) 2022-03-18 2023-03-17 Pharmaceutical recombinant human acid sphingomyelinase compositions and methods

Publications (1)

Publication Number Publication Date
AU2023235321A1 true AU2023235321A1 (en) 2024-10-31

Family

ID=86051983

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023235321A Pending AU2023235321A1 (en) 2022-03-18 2023-03-17 Pharmaceutical recombinant human acid sphingomyelinase compositions and methods

Country Status (12)

Country Link
US (1) US20230365946A1 (https=)
EP (1) EP4493684A1 (https=)
JP (1) JP2025509722A (https=)
KR (1) KR20240156645A (https=)
CN (1) CN119365593A (https=)
AR (1) AR128825A1 (https=)
AU (1) AU2023235321A1 (https=)
CA (1) CA3254814A1 (https=)
IL (1) IL315655A (https=)
MX (1) MX2024011382A (https=)
TW (1) TW202403043A (https=)
WO (1) WO2023178325A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4594462A1 (en) 2022-09-28 2025-08-06 Genzyme Corporation Systems and devices for producing biological products and methods of using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US20020137173A1 (en) * 2001-02-05 2002-09-26 Dae-Kyong Kim Membrane-associated sphingomyelinase derived from bovine brain, isolation method therefor and anti-sphingomyelinase monoclonal anitibody
US7527956B2 (en) * 2003-06-12 2009-05-05 Genzyme Corporation Modified human acid sphingomyelinase having increased activity, and methods for making the same
WO2008085988A1 (en) 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
KR20100103595A (ko) 2008-01-18 2010-09-27 에프. 호프만-라 로슈 아게 비-글라이코실화된 단백질의 정제
RU2012151132A (ru) 2010-05-19 2014-06-27 Ф. Хоффманн-Ля Рош Аг Хроматография с гиброфобным взаимодействием
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
EP2997036B1 (en) 2013-05-15 2021-03-03 Medimmune Limited Purification of recombinantly produced polypeptides
DK3728287T3 (da) 2017-12-19 2024-06-10 CSL Behring Lengnau AG Proteinoprensning og virusinaktivering med alkylglycosider
PY1939780A (es) 2018-05-25 2019-12-04 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida

Also Published As

Publication number Publication date
JP2025509722A (ja) 2025-04-11
TW202403043A (zh) 2024-01-16
WO2023178325A1 (en) 2023-09-21
IL315655A (en) 2024-11-01
KR20240156645A (ko) 2024-10-30
US20230365946A1 (en) 2023-11-16
AR128825A1 (es) 2024-06-19
CA3254814A1 (en) 2023-09-21
MX2024011382A (es) 2024-09-23
CN119365593A (zh) 2025-01-24
EP4493684A1 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
TWI403519B (zh) Ｆｇｆ２１突變體及其用途
CN102387784B (zh) 冻干的重组vwf配方
KR101398713B1 (ko) 조성물 및 조성물의 제조 방법
EP3016677B1 (en) Antibody formulations and methods
US20240327481A1 (en) Growth differentiation factor 15 fusion proteins
MD3672614T2 (ro) Vezicule extracelulare modificate și utilizări ale acestora
TW201141512A (en) Liquid formulations for long-acting erythropoietin conjugate
TWI835773B (zh) 組合物及使用方法
WO2013188181A1 (en) Fibroblast growth factor 21 proteins
AU2016201790A1 (en) Therapeutic nuclease compositions and methods
CN102257001A (zh) 治疗自体免疫和炎性病症的可溶性多肽
JP2020202841A (ja) Ｃ１エステラーゼ阻害因子融合タンパク質及びその使用
TWI897893B (zh) 含有血清白蛋白與生長激素之融合蛋白質之水性醫藥組成物
EP3318571B1 (en) Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase
EP4493684A1 (en) Pharmaceutical recombinant human acid sphingomyelinase compositions and methods
CA2906540C (en) Method of treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides
JP2025105975A (ja) 治療用タンパク質の製造方法
HK1202454A1 (en) Anti-p-selectin antibody formulation
CN112424347A (zh) 治疗酸性鞘磷脂酶缺乏症的药物组合物
TWI891671B (zh) 血清白蛋白與生長激素之融合蛋白質之製造方法
US20230338470A1 (en) Methods and compositions for treating ocular disorders with fasr
WO2025137648A1 (en) Compositions and methods for innate immune modulators
AU2024351533A1 (en) IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA
CN121985959A (en) IgA-depleting immunoglobulin formulations
CN117919401A (zh) 一种抗rbd抗体或其抗原结合片段的稳定的药物组合物